Patient registries may prove valuable in regulatory decisions, EMA study finds
Although patient registries can be heterogeneous in their quality and design, a new study in Drug Safety co-authored by an EMA official explains how patient registries could provide valuable data for regulatory decisions.
The authors explain how such registries can be used when randomized controlled trials are not feasible, such as with some rare diseases, or to meet postmarketing commitments.
“For products granted conditional marketing approval, registry studies may provide post-authorisation data to fulfil regulator-imposed specific obligations to confirm safety and/or effectiveness, as is the case with the recently authorised chimeric antigen receptor (CAR) T-cell products, tiagenlecleucel and axicabtagene ciloleucel,” the study says.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.